1. Home
  2. LVO vs CING Comparison

LVO vs CING Comparison

Compare LVO & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LiveOne Inc.

LVO

LiveOne Inc.

HOLD

Current Price

$4.49

Market Cap

65.9M

ML Signal

HOLD

CING

Cingulate Inc.

HOLD

Current Price

$4.96

Market Cap

64.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LVO
CING
Founded
2009
2012
Country
United States
United States
Employees
N/A
14
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
65.9M
64.5M
IPO Year
2010
N/A

Fundamental Metrics

Financial Performance
Metric
LVO
CING
Price
$4.49
$4.96
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
2
Target Price
$11.50
$34.50
AVG Volume (30 Days)
42.7K
218.6K
Earning Date
06-17-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
78.57
N/A
EPS
N/A
N/A
Revenue
$77,144,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$23.04
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.43
$3.16
52 Week High
$7.19
$11.89

Technical Indicators

Market Signals
Indicator
LVO
CING
Relative Strength Index (RSI) N/A 51.94
Support Level N/A $4.21
Resistance Level N/A $5.15
Average True Range (ATR) 0.00 0.28
MACD 0.00 0.02
Stochastic Oscillator 0.00 83.23

Price Performance

Historical Comparison
LVO
CING

About LVO LiveOne Inc.

LiveOne Inc creator-first, music, entertainment and technology platform focused on delivering premium experiences and content world'wide through paid users and live and virtual events. It is in the acquisition, distribution and monetization of live music events, Internet radio, podcasting/vodcasting and music-related membership, streaming and video content. It provide services through a dedicated over-the-top application powered by Slacker (LiveOne App) called LiveOne. The company has three operating segments, PodcastOne, Slacker and Media Group. The company generates majority of revenue from PodcastOne. The Company's operations are based in the United States.

About CING Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: